Targeting Hypoxia: Revival of Old Remedies
Tumour hypoxia is significantly correlated with patient survival and treatment outcomes. At the molecular level, hypoxia is a major driving factor for tumour progression and aggressiveness. Despite the accumulative scientific and clinical efforts to target hypoxia, there is still a need to find spec...
Guardado en:
Autores principales: | , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2f1a5fafb1e94ff4b5dcacc6df687a95 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:2f1a5fafb1e94ff4b5dcacc6df687a95 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:2f1a5fafb1e94ff4b5dcacc6df687a952021-11-25T16:52:43ZTargeting Hypoxia: Revival of Old Remedies10.3390/biom111116042218-273Xhttps://doaj.org/article/2f1a5fafb1e94ff4b5dcacc6df687a952021-10-01T00:00:00Zhttps://www.mdpi.com/2218-273X/11/11/1604https://doaj.org/toc/2218-273XTumour hypoxia is significantly correlated with patient survival and treatment outcomes. At the molecular level, hypoxia is a major driving factor for tumour progression and aggressiveness. Despite the accumulative scientific and clinical efforts to target hypoxia, there is still a need to find specific treatments for tumour hypoxia. In this review, we discuss a variety of approaches to alter the low oxygen tumour microenvironment or hypoxia pathways including carbogen breathing, hyperthermia, hypoxia-activated prodrugs, tumour metabolism and hypoxia-inducible factor (HIF) inhibitors. The recent advances in technology and biological understanding reveal the importance of revisiting old therapeutic regimens and repurposing their uses clinically.Nuria Vilaplana-LoperaMaxym BeshEui Jung MoonMDPI AGarticlehypoxiacancertirapazaminehyperthermiacarbogen breathingtumour metabolismMicrobiologyQR1-502ENBiomolecules, Vol 11, Iss 1604, p 1604 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
hypoxia cancer tirapazamine hyperthermia carbogen breathing tumour metabolism Microbiology QR1-502 |
spellingShingle |
hypoxia cancer tirapazamine hyperthermia carbogen breathing tumour metabolism Microbiology QR1-502 Nuria Vilaplana-Lopera Maxym Besh Eui Jung Moon Targeting Hypoxia: Revival of Old Remedies |
description |
Tumour hypoxia is significantly correlated with patient survival and treatment outcomes. At the molecular level, hypoxia is a major driving factor for tumour progression and aggressiveness. Despite the accumulative scientific and clinical efforts to target hypoxia, there is still a need to find specific treatments for tumour hypoxia. In this review, we discuss a variety of approaches to alter the low oxygen tumour microenvironment or hypoxia pathways including carbogen breathing, hyperthermia, hypoxia-activated prodrugs, tumour metabolism and hypoxia-inducible factor (HIF) inhibitors. The recent advances in technology and biological understanding reveal the importance of revisiting old therapeutic regimens and repurposing their uses clinically. |
format |
article |
author |
Nuria Vilaplana-Lopera Maxym Besh Eui Jung Moon |
author_facet |
Nuria Vilaplana-Lopera Maxym Besh Eui Jung Moon |
author_sort |
Nuria Vilaplana-Lopera |
title |
Targeting Hypoxia: Revival of Old Remedies |
title_short |
Targeting Hypoxia: Revival of Old Remedies |
title_full |
Targeting Hypoxia: Revival of Old Remedies |
title_fullStr |
Targeting Hypoxia: Revival of Old Remedies |
title_full_unstemmed |
Targeting Hypoxia: Revival of Old Remedies |
title_sort |
targeting hypoxia: revival of old remedies |
publisher |
MDPI AG |
publishDate |
2021 |
url |
https://doaj.org/article/2f1a5fafb1e94ff4b5dcacc6df687a95 |
work_keys_str_mv |
AT nuriavilaplanalopera targetinghypoxiarevivalofoldremedies AT maxymbesh targetinghypoxiarevivalofoldremedies AT euijungmoon targetinghypoxiarevivalofoldremedies |
_version_ |
1718412883802456064 |